Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia

Michaela Liedtke*, Tamara Dunn, Shira Dinner, Steven E. Coutré, Caroline Berube, Jason Gotlib, Samit Patel, Bruno Medeiros

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The survival of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor. We performed a retrospective analysis of 40 patients treated with five days of mitoxantrone 8mg/m2/day, etoposide 100mg/m2/day, and cytarabine 1000mg/m2/day (MEC). The complete remission rate was 30% and median remission duration was 11.2 months. Median overall survival was 6.5 months. In univariate analysis, patients in first relapse had improved overall survival compared to ≥second relapse (p=0.02). Thirty-day mortality rate was 7.5%. In relapsed or refractory ALL, MEC demonstrated moderate activity, but did not improve survival compared to published salvage chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)1441-1445
Number of pages5
JournalLeukemia Research
Volume38
Issue number12
DOIs
StatePublished - Dec 1 2014

Keywords

  • ALL
  • MEC
  • Salvage treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this